Medication education
About Mounjaro (tirzepatide)
Mounjaro is a prescription-only, once-weekly injectable medicine containing tirzepatide. Whether it is appropriate for you — and for what purpose — is a decision for a qualified doctor after an individual assessment.
- Active ingredient
- Tirzepatide
- How it acts
- GIP and GLP-1 receptor agonist
- Format
- Once-weekly injection
- Status
- Prescription-only
OverviewWhat Mounjaro is
Mounjaro is the brand name for tirzepatide, a prescription medicine given as a once-weekly injection under the skin.
Tirzepatide acts on two gut-hormone pathways — GIP and GLP-1 receptors — involved in appetite and blood-glucose regulation. This dual action is what distinguishes it from medicines that act on GLP-1 alone.
How it works, in plain language
Tirzepatide activates both GIP and GLP-1 receptors. In plain terms, this helps reduce appetite, increase feelings of fullness, slow stomach emptying and support blood-glucose regulation. Because it works on two pathways rather than one, its effects differ from single-pathway GLP-1 medicines.
Approved-use context in India
Tirzepatide (Mounjaro) has received marketing authorisation from India's drug regulator, CDSCO, as an adjunct to diet and exercise for adults with type 2 diabetes, and for chronic weight management in adults with obesity, or overweight with at least one weight-related condition.
Approval does not mean it is automatic or first-line for everyone. Whether it is appropriate for either purpose in your case is an individual clinical decision made by your doctor.
Why individual assessment is required
Mounjaro is a prescription-only medicine that is not suitable for everyone. A doctor must review your health, history and any contraindications before it is considered — and must decide which, if any, of its approved uses applies to you.
Important factors a doctor may review
- Your medical history and current health
- Whether your goal relates to type 2 diabetes, weight management, or both
- Existing medicines and possible interactions
- Personal and family history relevant to safety, including any thyroid C-cell tumour history
- Kidney, liver, pancreatic and gallbladder health where relevant
- Pregnancy or reproductive plans
- Whether the potential benefit outweighs the risk for you
Important contraindication categories
Mounjaro must not be used in certain situations. A doctor will check for these before considering it:
- A personal or family history of medullary thyroid carcinoma (MTC), or Multiple Endocrine Neoplasia syndrome type 2 (MEN2)
- A previous serious hypersensitivity (allergic) reaction to tirzepatide or any of its components
Important warnings and precautions
- Pancreatitis: inflammation of the pancreas has been reported; seek urgent care for severe, persistent abdominal pain.
- Hypoglycaemia: the risk of low blood sugar increases when tirzepatide is used with insulin or certain other diabetes medicines.
- Dehydration and kidney risk: significant vomiting or diarrhoea can cause dehydration, which may affect kidney function.
- Severe gastrointestinal conditions: not recommended in people with severe gastroparesis or severe gastrointestinal disease.
- Gallbladder problems: gallstones and related events have been reported.
- Thyroid C-cell tumours: seen in animal studies; relevance to humans is uncertain, which is why MTC/MEN2 history matters.
- Planned surgery or procedures involving anaesthesia or deep sedation: tell your care team you take this medicine, as slowed stomach emptying can be relevant.
General monitoring
If prescribed, your response, tolerability, weight, blood glucose (where relevant) and relevant laboratory markers are reviewed over time, and any dose adjustment is made by your treating clinician.
Common side effects
- Nausea, vomiting, diarrhoea or constipation — most common when starting or increasing a dose
- Reduced appetite, indigestion or abdominal discomfort
- Injection-site reactions such as redness or itching
Serious symptoms — seek medical attention
- Severe, persistent abdominal pain (possible pancreatitis)
- Signs of a serious allergic reaction, such as swelling of the face or throat, or difficulty breathing
- Persistent vomiting or diarrhoea leading to dehydration
- Symptoms of very low blood sugar if you also take certain diabetes medicines
Pregnancy and reproductive planning
Tirzepatide is not recommended during pregnancy. If you are pregnant, planning a pregnancy, or could become pregnant, tell your doctor before any treatment decision — reproductive planning is an explicit part of the clinical review.
If you take other diabetes medicines
If you take insulin or a sulfonylurea, using tirzepatide alongside them can increase the risk of low blood sugar. Any adjustment to your diabetes medicines must be made by your treating clinician — never on your own.
How the planned Saathya programme may support you
- Doctor-led assessment before any prescription decision
- Diagnostics to inform suitability, where appropriate
- Nutrition and strength support alongside treatment
- Dose and side-effect tracking with care-team escalation
- Ongoing monitoring and maintenance planning
Availability and pricing: Saathya Health is in pre-launch. The availability and pricing of any medication have not been announced, and joining the waitlist does not guarantee a prescription or any specific medicine.
Mounjaro — your questions
Sources
The pharmacological and safety information on this page is grounded in regulator-approved prescribing information. India-approval context refers to CDSCO records; non-Indian labels are cited only for general safety context and are not Indian approval evidence.
Join the early-access waitlist
Register your interest in Saathya Health. Joining creates no treatment commitment — eligibility is assessed separately, and it does not guarantee a consultation, a prescription or medicine availability.
Join the Waitlist